May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Kentucky's New Governor Could Change the Terms of Medicaid Expansion
Dr Lee Newcomer on Value Calculators and New Immuno-Oncology Agents
Ted Okon Outlines the Purpose of COA's Payer Exchange Summit